C
Charles A. Leath
Researcher at University of Alabama at Birmingham
Publications - 197
Citations - 4637
Charles A. Leath is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Ovarian cancer & Medicine. The author has an hindex of 30, co-authored 174 publications receiving 3357 citations. Previous affiliations of Charles A. Leath include University of Minnesota & San Antonio Military Medical Center.
Papers
More filters
Journal ArticleDOI
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman,Gini F. Fleming,Mark F. Brady,Elizabeth M. Swisher,Karina Dahl Steffensen,Michael Friedlander,Aikou Okamoto,Kathleen N. Moore,Noa Ben-Baruch,Theresa L. Werner,N.G. Cloven,Ana Oaknin,Paul DiSilvestro,Mark A. Morgan,Joo-Hyun Nam,Charles A. Leath,Shibani Nicum,Andrea R. Hagemann,Ramey D. Littell,David Cella,Sally Baron-Hay,Jesús García-Donas,Mika Mizuno,Katherine M. Bell-McGuinn,Danielle Sullivan,Bruce A. Bach,Sudipta Bhattacharya,Christine K. Ratajczak,Peter Ansell,Minh H. Dinh,Carol Aghajanian,Michael A. Bookman +31 more
TL;DR: Across all trial populations, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliporib maintenance therapy led to significantly longer progression-free survival than carboplati plus pac Litaxel induction therapy alone.
Journal ArticleDOI
Ovarian cancer, version 2.2020
Deborah K. Armstrong,Ronald D. Alvarez,Jamie N. Bakkum-Gamez,Lisa Barroilhet,Kian Behbakht,Andrew Berchuck,Lee-may Chen,Mihaela C. Cristea,Maria DeRosa,Eric L. Eisenhauer,David M. Gershenson,Heidi J. Gray,Rachel N. Grisham,Ardeshir Hakam,Angela Jain,Amer Karam,Gottfried E. Konecny,Charles A. Leath,Joyce F. Liu,Haider Mahdi,Lainie P. Martin,Daniela Matei,Michael T. McHale,Karen McLean,David Miller,David M. O'Malley,Sanja Percac-Lima,Elena Ratner,Steven W. Remmenga,Roberto Vargas,Theresa L. Werner,Emese Zsiros,Jennifer L. Burns,Anita M. Engh +33 more
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan,Amit M. Oza,Gary Richardson,Diane Provencher,Vincent L. Hansen,M. Buck,Setsuko K. Chambers,Prafull Ghatage,C. H. Pippitt,John V. Brown,Allan Covens,Raj V. Nagarkar,Margaret Davy,Charles A. Leath,Hoa Nguyen,Daniel E. Stepan,David M. Weinreich,Marjan Tassoudji,Yu Nien Sun,Ignace Vergote +19 more
TL;DR: AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile, and the data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.
Journal ArticleDOI
A multi-institutional review of outcomes of endometrial stromal sarcoma
Charles A. Leath,Warner K. Huh,Johnny Hyde,David E. Cohn,Kimberly Resnick,Nicholas P. Taylor,Matthew A. Powell,David G. Mutch,William H. Bradley,Melissa A. Geller,Peter A. Argenta,Michael A. Gold +11 more
TL;DR: Low-grade and high-grade endometrial stromal sarcomas represent two distinct clinical entities and should be treated as such and the need for aggressive cytoreduction is suggested.
Journal ArticleDOI
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Richard T. Penson,Ricardo Villalobos Valencia,David Cibula,Nicoletta Colombo,Charles A. Leath,Mariusz Bidziński,Jae Weon Kim,Joo-Hyun Nam,Radoslaw Madry,Carlos Alberto Hernández,Paulo Alexandre Ribeiro Mora,Sang Young Ryu,Tsveta Milenkova,Elizabeth S. Lowe,Laura Barker,Giovanni Scambia +15 more
TL;DR: Olaparib resulted in statistically significant and clinically relevant improvements in ORR and PFS compared with nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at least 2 prior lines of platinum-based chemotherapy.